Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP583953.RAcxfa7IBrVuCGIPEnWxw9jkSht1EvcJMYT77Rlufb2oI130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP583953.RAcxfa7IBrVuCGIPEnWxw9jkSht1EvcJMYT77Rlufb2oI130_provenance.
• NP196795.RAjTPCapJWlCGCfEy8x5P9x1zjfe6aA5wgJ9Di32qLvB0130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP196795.RAjTPCapJWlCGCfEy8x5P9x1zjfe6aA5wgJ9Di32qLvB0130_provenance.
• NP791601.RAe6dPRluhBYO2lOmDS3ifZZhh7N5BqJMUTF9C4CSubyA130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP791601.RAe6dPRluhBYO2lOmDS3ifZZhh7N5BqJMUTF9C4CSubyA130_provenance.
• NP319220.RAj35hm2knHWvz8NWlDb6OVwd-CTJMz47c05MFog_n7Z4130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP319220.RAj35hm2knHWvz8NWlDb6OVwd-CTJMz47c05MFog_n7Z4130_provenance.
• NP362864.RA_4y703k-bVyEhcRQ8QAGHFn-J5ysdo6sL348tr64wms130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP362864.RA_4y703k-bVyEhcRQ8QAGHFn-J5ysdo6sL348tr64wms130_provenance.
• NP801212.RAjlkZTbek_G7hNDK5t-ra0n7kv6Ni_KyB7Erj5MsuC7c130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP801212.RAjlkZTbek_G7hNDK5t-ra0n7kv6Ni_KyB7Erj5MsuC7c130_provenance.
• NP305237.RA2-_qRiVdoCTmnahh5KkmyDB-BOaLY7XLbRatVyKzB6M130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP305237.RA2-_qRiVdoCTmnahh5KkmyDB-BOaLY7XLbRatVyKzB6M130_provenance.
• NP512296.RA3EP7Qm7oDRw5g0XTOr2FWNWUQ9oKswKa5Mwp8CFv7mA130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512296.RA3EP7Qm7oDRw5g0XTOr2FWNWUQ9oKswKa5Mwp8CFv7mA130_provenance.
• NP774221.RA7cQj27GLilgdNLSFZlybEmQ5UtldRLW11a67XwLgiR0130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP774221.RA7cQj27GLilgdNLSFZlybEmQ5UtldRLW11a67XwLgiR0130_provenance.
• NP885165.RADFe6ovkbmqaK-5Va5ALXEI1W-cGylLXV54UlfqrxK5M130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885165.RADFe6ovkbmqaK-5Va5ALXEI1W-cGylLXV54UlfqrxK5M130_provenance.
• NP555594.RAM2HD2Uj4Wdlbv1wOcW4CrSbZp-iroQc-BzTS8nxybSw130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP555594.RAM2HD2Uj4Wdlbv1wOcW4CrSbZp-iroQc-BzTS8nxybSw130_provenance.
• NP395018.RA8U69YhUrK3r2h_m9tV_kpttkXnsYOVjsH3IL9BIvYhk130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP395018.RA8U69YhUrK3r2h_m9tV_kpttkXnsYOVjsH3IL9BIvYhk130_provenance.
• NP901218.RAdYmV0ySYeeiIneWZHmekTaAZJ_ksJSlgon38Rn7Nepc130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP901218.RAdYmV0ySYeeiIneWZHmekTaAZJ_ksJSlgon38Rn7Nepc130_provenance.
• NP901253.RAZE6HNjBFQrd8h6OyllsunQlET1w7dB8U067Dok7Rmck130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP901253.RAZE6HNjBFQrd8h6OyllsunQlET1w7dB8U067Dok7Rmck130_provenance.
• NP885162.RA2gp5Q5EXjdbx3zG1rsDg5pIsmqZlYBGaoZ0J6zTi6i0130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885162.RA2gp5Q5EXjdbx3zG1rsDg5pIsmqZlYBGaoZ0J6zTi6i0130_provenance.
• NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_provenance.
• NP885168.RA1Ch25nf_lYOiZo-XlijZov3kZsgFmlwvDf6MoIT1i5Y130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885168.RA1Ch25nf_lYOiZo-XlijZov3kZsgFmlwvDf6MoIT1i5Y130_provenance.
• NP395569.RAIYQPA5JRLW8xEHvWgLpsF9VFkmFtc6pvIRf8Bxmxnn4130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP395569.RAIYQPA5JRLW8xEHvWgLpsF9VFkmFtc6pvIRf8Bxmxnn4130_provenance.
• NP885163.RAWZImYb_nlAKgf8QAZFdWVxNuUBN24iyJaSizwPq8_pM130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885163.RAWZImYb_nlAKgf8QAZFdWVxNuUBN24iyJaSizwPq8_pM130_provenance.
• NP248854.RAsCpaxcg14KEN9ze7jhWSXJ7S2k1O9ZKcI5luLLczsPI130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP248854.RAsCpaxcg14KEN9ze7jhWSXJ7S2k1O9ZKcI5luLLczsPI130_provenance.
• NP248223.RAtjBZ9fq6gWCmqXChRjylHPRqsW0Q5z6DlJaXkNKERKc130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP248223.RAtjBZ9fq6gWCmqXChRjylHPRqsW0Q5z6DlJaXkNKERKc130_provenance.
• NP885169.RAhn5JXNQg8EahNsuOoAlPD3awyM5oojynPWTWJbaZpww130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885169.RAhn5JXNQg8EahNsuOoAlPD3awyM5oojynPWTWJbaZpww130_provenance.